

2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

<https://marketpublishers.com/r/266C943656FEN.html>

Date: October 2015

Pages: 620

Price: US\$ 7,840.00 (Single User License)

ID: 266C943656FEN

Abstracts

Complete report **\$9,800**. DataPack (test volumes, sales forecasts, supplier shares) **\$6,400**.

“**2016 New Frontiers in the US Cancer Diagnostics Market**” is VPGMarketResearch’s new study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

U.S. Market Overview

- Five-year test volume and sales projections.
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
- Estimated universe of laboratories performing cancer diagnostic testing.
- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.
- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin,

Cathepsin, CEA,

Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,

Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,

Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,

Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,

Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,

Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product

suppliers by individual test.

- Five-year test volume and sales forecasts

for major tumor markers by market segment, including:

- Hospitals

- Commercial/Private Laboratories

- Physician Offices/Group Practices

- Cancer Clinics

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers

used for cancer testing, including their operating characteristics,

features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods,

biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,

chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies

and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including

CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities

and research centers developing new cancer diagnostic tests

and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers

and start-up firms developing innovative

technologies and products, including their sales,

product portfolios, marketing tactics, collaborative

arrangements, and new products in R&D.

- The companies analyzed in the report include

- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- DiaSorin
- Eiken Chemical
- Elitech Group
- Epigenomics

- Enterix
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartech
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals

- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zilla

Contains 620 pages and 103 tables

Contents

I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VI. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

ADA

B-Protein

PNP

5'-Nucleotidase

27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

- 30. Colony Stimulating Factors
- 31. Lymphokines
 - Alpha-Interferon
 - B Cell Growth Factors
 - B Cell Growth Factor (BCGF)
 - Gamma-Interferon
 - Interleukin-1 (IL-1)
 - Macrophage Activating Factor
- 32. Immunohistochemical Stains
- 33. Emerging Tumor Markers
 - N-Acetylglucosamine
 - Actin
 - Alpha-Actin
 - Antineuronal Antibodies
 - 7B2
 - B72.3
 - Bax
 - BCD-F9
 - BLCA-4
 - Blood Group Antigens A,B,H
 - CA
 - CA 72-4/TAG-72
 - CA
 - CA-242
 - CA-549
 - CAM
 - CAR-3
 - Cathepsin-D
 - Chromogranin A and B
 - Cluster 1 Antigen
 - Cluster-5/5A Antigen
 - CTA
 - CU18
 - DR-70
 - DU-PAN-2
 - Endometrial Bleeding Associated Factor
 - Endostatin
 - Epithelial Membrane Antigen
 - Feulgen Hydrolysis

Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides

P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TAB A
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villin

C. Instrumentation Review And Market Needs

D. Current and Emerging Technologies

1. Molecular Diagnostics

- a. Technology Overview
- b. Amplification Methods
- c. Sequencing
- d. Microarrays/Biochips

2. Monoclonal and Polyclonal Antibodies

3. Immunoassays

- a. Technological Principle
- b. Radioimmunoassay (RIA)
- c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
- e. Luminescence
- Chemiluminescence
- Bioluminescence
- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- E. Personal Testing

VII. U.S.A.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales And Market Shares

VIII. COMPETITIVE PROFILES

Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca Pharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radiant Pharmaceuticals

Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

IX. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGY AND APPLICATIONS

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast
By Market Segment

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates Per 100,000 Population

U.S., Laboratories Performing Tumor Marker Tests by Market Segment

U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.S., Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test

Volume

U.S., Physician Office Laboratories Performing Tumor Marker Tests By Practice Size
U.S., Total Tumor Marker Test Volume Forecast by Market Segment
U.S., All Market Segments Major Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
U.S., Total Tumor Marker Sales Forecast by Market Segment
U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Colon-specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Cytokeratins Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Estrogen Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Interferons Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Interleukins Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Occult Blood Test Volume And Diagnostics Sales Forecast by Market Segment
U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
U.S., Total Tumor Marker Sales By Major Supplier
U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
U.S., AFP Testing Market Diagnostics Sales by Major Supplier
U.S., Beta-2 Microglobulin Testing Market Diagnostics Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
U.S., CEA Testing Market Diagnostics Sales by Major Supplier
U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
U.S., HCG Testing Market Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics Sales by Major Supplier
U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

Product link: <https://marketpublishers.com/r/266C943656FEN.html>

Price: US\$ 7,840.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/266C943656FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

